



Pharmacogenomics and Hypertension: Problems and Prospects

Guest Editors:

Prof. Dr. Brian L. Rayner

Division of Nephrology and
Hypertension, University of Cape
Town, Cape Town, South Africa

Prof. Dr. Collet Dandara

Platform for Pharmacogenomics
Research and Translation
(PREMED), South African Medical
Research Council & Division of
Human Genetics, Faculty of
Health Sciences, University of
Cape Town, Cape Town, South
Africa

Deadline for manuscript
submissions:

25 November 2024

Message from the Guest Editors

Arterial hypertension has a strong underlying hereditary and environmental basis. Treatment has remained empiric, control rates are suboptimal, and there is minimal translation of genetics from the bench to the clinic. Although rare monogenic forms of hypertension with a distinct phenotype were initially well documented and provided specific treatments, the overall genetic risk for hypertension was considered to be polygenetic in origin. The initial GWAS studies could only explain 2% of the overall risk, which led to a degree of nihilism in relation to the pharmacogenetics of hypertension.

The aim of this Special Issue is to review and publish cutting-edge research on new developments in the understanding of the genetics of arterial hypertension, the translation of genetic research to the clinic, and future directions for pharmacogenomics. We are soliciting original articles related to understanding the genetic architecture of hypertension, genetic risk scoring, Mendelian randomization, epigenetics, the pharmacokinetics and pharmacodynamics of antihypertensive drugs, translational research, and state-of-the-art manuscripts on the status of pharmacogenomics and future directions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA

2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)